Chorny Michael, Fishbein Ilia, Adamo Richard F, Forbes Scott P, Folchman-Wagner Zoë, Alferiev Ivan S
Division of Cardiology Research, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Methodist Debakey Cardiovasc J. 2012 Jan;8(1):23-7. doi: 10.14797/mdcj-8-1-23.
Magnetic guidance is a physical targeting strategy with the potential to improve the safety and efficacy of a variety of therapeutic agents--including small-molecule pharmaceuticals, proteins, gene vectors, and cells--by enabling their site-specific delivery. The application of magnetic targeting for in-stent restenosis can address the need for safer and more efficient treatment strategies. However, its translation to humans may not be possible without revising the traditional magnetic targeting scheme, which is limited by its inability to selectively guide therapeutic agents to deep localized targets. An alternative two-source strategy can be realized through the use of uniform, deep-penetrating magnetic fields in conjunction with vascular stents included as part of the magnetic setup and the platform for targeted delivery to injured arteries. Studies showing the feasibility of this novel targeting strategy in in-stent restenosis models and considerations in the design of carrier formulations for magnetically guided antirestenotic therapy are discussed in this review.
磁导向是一种物理靶向策略,通过实现治疗剂的位点特异性递送,有潜力提高包括小分子药物、蛋白质、基因载体和细胞在内的多种治疗剂的安全性和有效性。磁靶向在支架内再狭窄中的应用可以满足对更安全、更有效治疗策略的需求。然而,如果不修改传统的磁靶向方案,可能无法将其应用于人体,传统磁靶向方案受到无法将治疗剂选择性引导至深部局部靶点的限制。通过使用均匀的、具有深度穿透性的磁场,结合作为磁装置一部分的血管支架以及用于靶向递送至受损动脉的平台,可以实现另一种双源策略。本文综述了在支架内再狭窄模型中这种新型靶向策略的可行性研究以及磁导向抗再狭窄治疗载体制剂设计中的考虑因素。